Center for Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.
Mol Cell Proteomics. 2012 Jun;11(6):M111.015479. doi: 10.1074/mcp.M111.015479. Epub 2012 Feb 15.
Allogeneic hematopoietic stem cell transplantation (SCT) is the only curative therapy for many malignant and nonmalignant conditions. Idiopathic pneumonia syndrome (IPS) is a frequently fatal complication that limits successful outcomes. Preclinical models suggest that IPS represents an immune mediated attack on the lung involving elements of both the adaptive and the innate immune system. However, the etiology of IPS in humans is less well understood. To explore the disease pathway and uncover potential biomarkers of disease, we performed two separate label-free, proteomics experiments defining the plasma protein profiles of allogeneic SCT patients with IPS. Samples obtained from SCT recipients without complications served as controls. The initial discovery study, intended to explore the disease pathway in humans, identified a set of 81 IPS-associated proteins. These data revealed similarities between the known IPS pathways in mice and the condition in humans, in particular in the acute phase response. In addition, pattern recognition pathways were judged to be significant as a function of development of IPS, and from this pathway we chose the lipopolysaccaharide-binding protein (LBP) protein as a candidate molecular diagnostic for IPS, and verified its increase as a function of disease using an ELISA assay. In a separately designed study, we identified protein-based classifiers that could predict, at day 0 of SCT, patients who: 1) progress to IPS and 2) respond to cytokine neutralization therapy. Using cross-validation strategies, we built highly predictive classifier models of both disease progression and therapeutic response. In sum, data generated in this report confirm previous clinical and experimental findings, provide new insights into the pathophysiology of IPS, identify potential molecular classifiers of the condition, and uncover a set of markers potentially of interest for patient stratification as a basis for individualized therapy.
异基因造血干细胞移植(SCT)是许多恶性和非恶性疾病的唯一治愈性治疗方法。特发性肺炎综合征(IPS)是一种经常致命的并发症,限制了成功的结果。临床前模型表明,IPS 代表了一种针对肺部的免疫介导攻击,涉及适应性和固有免疫系统的元素。然而,人类 IPS 的病因尚不清楚。为了探索疾病途径并发现疾病的潜在生物标志物,我们进行了两项独立的无标记、蛋白质组学实验,定义了患有 IPS 的异基因 SCT 患者的血浆蛋白质谱。来自无并发症 SCT 受者的样本作为对照。最初的发现研究旨在探索人类的疾病途径,确定了一组 81 种与 IPS 相关的蛋白质。这些数据揭示了在小鼠中已知的 IPS 途径与人类状况之间的相似性,特别是在急性期反应中。此外,模式识别途径被认为与 IPS 的发展有关,并且从该途径中,我们选择了脂多糖结合蛋白(LBP)蛋白作为 IPS 的候选分子诊断,并使用 ELISA 测定法验证了其作为疾病功能的增加。在单独设计的研究中,我们确定了蛋白质分类器,可以在 SCT 的第 0 天预测:1)进展为 IPS 和 2)对细胞因子中和治疗有反应的患者。使用交叉验证策略,我们构建了疾病进展和治疗反应的高度预测性分类器模型。总之,本报告中生成的数据证实了以前的临床和实验发现,为 IPS 的病理生理学提供了新的见解,确定了该疾病的潜在分子分类器,并发现了一组可能对患者分层有兴趣的标志物,作为个体化治疗的基础。